[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610574":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":24,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":24,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":24,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":24,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"SightGlass Vision, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SightGlass Vision Test Arm 1","EXPERIMENTAL","Single vision, impact-resistant spectacle lenses",[13],"Device: Novel spectacle lens design",{"label":15,"type":10,"description":11,"interventionNames":16},"SightGlass Vision Test Arm 2",[17],"Device: Spectacle lenses",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DEVICE","Novel spectacle lens design","Use of lenses may reduce the rate of progression of juvenile myopia",[9],null,{"type":20,"name":26,"description":22,"armGroupLabels":27,"otherNames":24},"Spectacle lenses",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Jennifer Hill","CONTACT","6783614877","jhill@sightglassvision.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Midwestern University Arizona College of Optometry","RECRUITING","Glendale","Arizona","85308","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-112.18599,33.53865,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":24,"phoneExt":24,"email":24},"Javier Gantes-Nunez",{"type":53,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100610574","mobility-performance-in-daily-activities-among-children-wearing-spectacle-lenses-100610574",false,"NCT07229352","Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses","Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses","Inclusion Criteria:\n\nA participant is eligible for inclusion in the study if they meet the following criteria:\n\n* Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent\u002Fassent.\n* Can achieve a corrected visual acuity of 20\u002F20 best-corrected (or equivalent logMAR).\n* Have undergone a self-reported oculo-visual examination within the past two years.\n* Have no active ocular disease.\n* Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.\n* Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.\n* The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.\n\nExclusion Criteria:\n\nA participant will be excluded from the study if they meet any of the following conditions:\n\n* Have any systemic disease that affects ocular health.\n* Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.\n* Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.\n* Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.\n* Have known developmental delays.\n* Have participated in another clinical study in the last 7 days",true,"ALL","6 Years","12 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"NA","The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).",[73,74,75],"Myopia","Myopia Progression","Juvenile Myopia","2026-04-29",{"date":78,"type":79},"2026-04-30","ACTUAL",{"date":81,"type":79},"2026-02-02",{"date":83,"type":67},"2027-07-01",{"name":5,"class":6},1]